Statin use after cancer diagnosis and survival among patients with cancer
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Purpose The association between statin use and cancer survival has been investigated in previous studies with conflicting findings. This study aimed to assess the association between statin use following cancer diagnosis and survival in six common cancers using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Methods Individuals aged ≥ 66 years diagnosed with prostate cancer, colorectal cancer, lung cancer, bladder cancer, pancreatic cancer, or non-Hodgkin lymphoma (NHL) from 2008 through 2017 were identified. Statin use was defined as two or more statin prescription fills after cancer diagnosis. Time-dependent Cox proportional hazard regression models were used to estimate the association between statin use and cancer-specific mortality for each cancer. Results This study included 34,618 patients with prostate cancer (median follow-up 4.0 years), 20,579 with colorectal cancer (2.9 years), 20,133 with lung cancer (1.7 years), 6,163 with bladder cancer (2.1 years), 4,538 with pancreatic cancer (0.8 years), and 3,270 with NHL (2.9 years). Statin use post-diagnosis was associated with a reduced risk of cancer-specific mortality in lung cancer (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.74-0.88) and pancreatic cancer (HR, 0.72; 95% CI, 0.59-0.87). The association was not statistically significant for prostate cancer, colorectal cancer, bladder cancer, or NHL. A dose-response relationship by duration of statin use was observed in lung cancer…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from large population-based cohorts demonstrates mixed results regarding the relationship between statin use and PDAC incidence or survival outcome, with some cohorts showing variable protective effects and others showing a survival benefit of statin exposure, as shown in Table 1”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
In the citing paper
“Guo et al. reported a benefit on OS for the PDAC patients treated with statins after diagnosis compared with the PDAC patients never treated with statins.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
In the citing paper
“with higher benefits on OS in the 1–2 years category compared to <1 category, and respectively 2–3 years category compared to 1–2 years category, with a ptrend value of 0.04 (Guo et al., 2025).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182 · cited 1×
“…selection bias due to the inclusion of prevalent users (individuals with pre-diagnosis statin exposure) and immortal time bias due to inappropriately classifying unexposed survival time before statin initiation as exposed, which could lead to overestimation of the benefits of statins [17–19].”
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030 · cited 1×
“All of the previous cohort studies on pancreatic cancer either only evaluated overall survival [34, 39–44] or only focused on pre-diagnosis use [45].”
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680 · cited 1×
“Statins have been shown to be pro-angiogenic at low therapeutic concentrations but anti-angiogenic at high concentrations in vitro [36].”
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Shrank, W. H., Patrick, A. R., & Alan Brookhart, M. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1609-1 · Cited by 630 · cited 1×
“This suggests that any potential protective effect of statins may be exhibited only with long-term use in prostate cancer, but the influence of healthy adherer bias cannot be ruled out [35].”
Salami, J. A., Warraich, H., Valero-Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4700 · Cited by 370
Cholesterol Treatment Trialists' (CTT) Collaboration (2012) · PLoS ONE · doi:10.1371/journal.pone.0029849 · Cited by 351 · cited 2×
“A meta-analysis of clinical trials found no statistically significant difference in the rate ratios of cancer death between hydrophilic and lipophilic statin use [11].”
Danaei, G., Tavakkoli, M., & Hernán, M. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 264
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196 · cited 2×
“Besides their impact on reducing cholesterol levels, they have also been shown to exert inhibitory effects on cancer cells through inhibition of cell proliferation, reduction of invasiveness and metastasis, and promotion of apoptosis [2–4].”
Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer
Emilsson, L., García-Albéniz, X., Logan, R. W., Caniglia, E. C., Kalager, M., & Hernán, M. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2752 · Cited by 188 · cited 2×
“…selection bias due to the inclusion of prevalent users (individuals with pre-diagnosis statin exposure) and immortal time bias due to inappropriately classifying unexposed survival time before statin initiation as exposed, which could lead to overestimation of the benefits of statins [17–19].”
Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview
Pazzagli, L., Linder, M., Zhang, M., Vágó, E., Stang, P., Myers, D., Andersen, M. T., & Bahmanyar, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4372 · Cited by 169 · cited 1×
“With prospective filling of the gaps [23], a patient was considered exposed for 60 days after the last supply elapsed.”
Hanai, J., Doro, N., Sasaki, A. T., Kobayashi, S., Cantley, L. C., Seth, P., & Sukhatme, V. P. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22895 · Cited by 165
(2019) · Journal of the National Cancer Institute Monographs · doi:10.1093/jncimonographs/lgz029 · Cited by 159 · cited 1×
“The Medicare claims files include information on inpatient care (Part A), physician service and outpatient care (Part B), and prescription drugs (Part D) for individuals over age 65 in the USA [22].”
Pleiotropic effects of statins: A focus on cancer
Ahmadi, M., Amiri, S., Pecic, S., Machaj, F., Rosik, J., Łos, M. J., Alizadeh, J., Mahdian, R., da Silva Rosa, S. C., Schaafsma, D., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165968 · Cited by 159
Han, J.-Y., Lee, S.-H., Yoo, N. J., Hyung, L. S., Moon, Y. J., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2525 · Cited by 156 · cited 2×
“However, statin therapy did prolong overall survival in a subgroup of advanced stage non-small cell lung cancer (NSCLC) patients [16].”
Chubak, J., Boudreau, D. M., Wirtz, H. S., McKnight, B., & Weiss, N. S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt211 · Cited by 145 · cited 2×
“Lagging of the exposure also mitigated confounding due to disease progression and reverse causation [27].”
Manthravadi, S., Shrestha, A., & Madhusudhana, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30185 · Cited by 142 · cited 1×
“Consistent with the in vitro evidence, many observational studies suggest a reduction of cancer-specific mortality associated with statin use in a number of cancers, including breast cancer [5, 6], colorectal cancer [7], lung cancer [8], prostate cancer [9], and pancreatic cancer [10].”
Hong, J. Y., Nam, E. M., Lee, J., Park, J. O., Lee, S., Song, S.-Y., Choi, S. H., Heo, J. S., Park, S. H., Lim, H. Y., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2328-1 · Cited by 134 · cited 1×
“Specifically, in trials of patients with advanced stage cancers, including small cell lung cancer [13], colorectal cancer [14], and pancreatic cancer [15], the addition of statins to standard chemotherapy offered no additional benefit compared with chemotherapy alone.”
Liu, B., Yi, Z., Guan, X., Zeng, Y.-X., & Ma, F. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4246-0 · Cited by 123 · cited 1×
“Consistent with the in vitro evidence, many observational studies suggest a reduction of cancer-specific mortality associated with statin use in a number of cancers, including breast cancer [5, 6], colorectal cancer [7], lung cancer [8], prostate cancer [9], and pancreatic cancer [10].”
Seckl, M. J., Ottensmeier, C. H., Cullen, M., Schmid, P., Ngai, Y., Muthukumar, D., Thompson, J., Harden, S., Middleton, G., Fife, K. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7391 · Cited by 116 · cited 2×
“Specifically, in trials of patients with advanced stage cancers, including small cell lung cancer [13], colorectal cancer [14], and pancreatic cancer [15], the addition of statins to standard chemotherapy offered no additional benefit compared with chemotherapy alone.”
Hoffmeister, M., Jansen, L., Rudolph, A., Toth, C., Kloor, M., Roth, W., Bläker, H., Chang-Claude, J., & Brenner, H. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv045 · Cited by 115 · cited 2×
“In addition to the threat of prevalent user bias, it has been suggested that failure to adjust for confounders such as stage at diagnosis could have led to spuri-ously significant associations in some studies [56].”
Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803
Ng, K., Ogino, S., Meyerhardt, J. A., Chan, J. A., Chan, A. T., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Mayer, R. J., Benson, A. B., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr307 · Cited by 100 · cited 1×
“Our findings are in line with several studies that found a null association [56–58].”
Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer
Larsen, S. B., Dehlendorff, C., Skriver, C., Dalton, S. O., Jespersen, C. G., Borre, M., Brasso, K., Nørgaard, M., Johansen, C., Sørensen, H. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8981 · Cited by 94
Lim, S. H., Kim, T. W., Hong, Y. S., Han, S.-W., Lee, K.-H., Kang, H. J., Hwang, I. G., Lee, J. Y., Kim, H. S., Kim, S. T., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.371 · Cited by 90 · cited 1×
“Specifically, in trials of patients with advanced stage cancers, including small cell lung cancer [13], colorectal cancer [14], and pancreatic cancer [15], the addition of statins to standard chemotherapy offered no additional benefit compared with chemotherapy alone.”
The effect of statins on survival in patients with stage IV lung cancer
Lin, J. J., Ezer, N., Sigel, K. M., Mhango, G., & Wisnivesky, J. P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.006 · Cited by 86 · cited 1×
“For lung cancer, our findings of an inverse association between statin use and risk of lung cancer death are similar to two previous SEER-Medicare studies [37, 38].”
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer
Huang, B. Z., Chang, J. I., Li, E., Xiang, A. H., & Wu, B. U. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw275 · Cited by 75 · cited 2×
“All of the previous cohort studies on pancreatic cancer either only evaluated overall survival [34, 39–44] or only focused on pre-diagnosis use [45].”
Li, Y., He, X., Ding, Y., Chen, H., & Sun, L. (2019) · Cancer Medicine · doi:10.1002/cam4.2151 · Cited by 75 · cited 2×
“The most recent meta-analysis of eight cohort studies found a risk reduction in colorectal cancer death (pooled HR, 0.79; 95% CI, 0.70–0.89), again with significant between-study heterogeneity [7].”
InfluentialFarooqi, M. A. M., Malhotra, N., Mukherjee, S. D., Sanger, S., Dhesy-Thind, S. K., Ellis, P., & Leong, D. P. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209486 · Cited by 73
Jeon, C. Y., Pandol, S. J., Wu, B., Cook-Wiens, G., Gottlieb, R. A., Merz, N. B., & Goodman, M. T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121783 · Cited by 69 · cited 1×
“All of the previous cohort studies on pancreatic cancer either only evaluated overall survival [34, 39–44] or only focused on pre-diagnosis use [45].”
Nowakowski, G. S., Maurer, M. J., Habermann, T. M., Ansell, S. M., Macon, W. R., Ristow, K. M., Allmer, C., Slager, S. L., Witzig, T. E., & Cerhan, J. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4245 · Cited by 68 · cited 1×
“Other studies have shown either a null association [64, 65] or improved survival [64, 66] in different NHL subtypes.”
Jian-Yu, E., Graber, J. M., Lu, S.-E., Lin, Y., Lu-Yao, G., & Tan, X.-L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170412145232 · Cited by 67 · cited 2×
“The most recent meta-analysis of the studies found improved overall survival in statin users (pooled HR, 0.75; 95% CI, 0.59–0.90), although with significant heterogeneity between the studies [10].”
InfluentialChen, J., Lan, T., Hou, J., Zhang, J., An, Y., Tie, L., Pan, Y., Liu, J., & Li, X. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.01.015 · Cited by 64 · cited 1×
“Aside from their EGFR-related effects, statins have also been shown to sensitize NSCLC cells to standard platinum-based chemotherapy by inhibiting AKT activation and upregulating TIMP-1 [33].”
Nakai, Y., Isayama, H., Sasaki, T., Mizuno, S., Sasahira, N., Kogure, H., Kawakubo, K., Yamamoto, N., Hirano, K., Ijichi, H., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825de678 · Cited by 63
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients
Lee, H. S., Lee, S. H., Lee, H. J., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., & Bang, S. (2016) · Medicine · doi:10.1097/md.0000000000003607 · Cited by 58
Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer
Wu, B. U., Chang, J., Jeon, C. Y., Pandol, S. J., Huang, B., Ngor, E. W., Difronzo, A. L., & Cooper, R. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.217 · Cited by 57 · cited 1×
“All of the previous cohort studies on pancreatic cancer either only evaluated overall survival [34, 39–44] or only focused on pre-diagnosis use [45].”
Xia, D., Hu, Z., Tian, Y., & Zeng, F. J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s187690 · Cited by 57 · cited 2×
“A meta-analysis of three cohort studies found a pooled HR of 0.89 (95% CI, 0.84–0.94) between statin use and lung cancer-specific mortality, although with high between-study heterogeneity [8].”
InfluentialHwang, K., Kwon, S., Kim, Y. S., Park, D., Kim, B.-R., Yoon, K., Jeong, E., & Kim, H.-R. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.02.026 · Cited by 55 · cited 1×
“Statins can overcome resistance to EGFR tyrosine kinase inhibitors in NSCLC cells harboring EGFR mutations by targeting the AKT/β-catenin signaling pathway [31].”
Abdel-Rahman, O. M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1992-3 · Cited by 54 · cited 1×
“Our results also align with those from a pooled analysis of two phase III clinical trials [46].”
Rompay, M. I. V., Solomon, K. R., Nickel, J. C., Ranganathan, G., Kantoff, P. W., & McKinlay, J. B. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.033 · Cited by 54
Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer
Kozak, M. M., Anderson, E. M., von Eyben, R., Pai, J. S., Poultsides, G. A., Visser, B. C., Norton, J. A., Koong, A. C., & Chang, D. T. (2016) · Pancreas · doi:10.1097/mpa.0000000000000470 · Cited by 50
Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort
Lash, T. L., Riis, A. H., Ostenfeld, E. B., Erichsen, R., Vyberg, M., Ahern, T. P., & Thorlacius‐Ussing, O. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww245 · Cited by 47
da Silva, R. D., Xylinas, E. N., Kluth, L. A., Crivelli, J. J., Chrystal, J., Chade, D. C., Guglielmetti, G., Pycha, A., Lotan, Y., Karakiewicz, P. I., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.003 · Cited by 42
Tan, P., Wei, S., Yang, L., Tang, Z., Cao, D., Liu, L., Lei, J., Yu, F., Gao, L., & Wei, Q. (2016) · Scientific Reports · doi:10.1038/srep29106 · Cited by 39 · cited 1×
“Consistent with the in vitro evidence, many observational studies suggest a reduction of cancer-specific mortality associated with statin use in a number of cancers, including breast cancer [5, 6], colorectal cancer [7], lung cancer [8], prostate cancer [9], and pancreatic cancer [10].”
Anderson-Carter, I., Posielski, N., Liou, J.-I., Khemees, T. A., Downs, T. M., Abel, E. J., Jarrard, D. F., & Richards, K. A. (2019) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.11.017 · Cited by 38 · cited 1×
“Our findings are similar to several previous studies that reported a null association [47–50], in contrast with other studies that found a significant association [51–54].”
Ung, M. H., MacKenzie, T. A., Onega, T., Amos, C. I., & Cheng, C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.022 · Cited by 37 · cited 1×
“For lung cancer, our findings of an inverse association between statin use and risk of lung cancer death are similar to two previous SEER-Medicare studies [37, 38].”
Crosstalk between Statins and Cancer Prevention and Therapy: An Update
Grabarek, B. O., Boroń, D., Morawiec, E., Michalski, P., Palazzo-Michalska, V., Pach, Ł., Dziuk, B., Świder, M., & Zmarzły, N. (2021) · Pharmaceuticals · doi:10.3390/ph14121220 · Cited by 36
Caon, J., Paquette, M., Hamm, J., & Pickles, T. (2014) · Prostate Cancer · doi:10.1155/2014/184297 · Cited by 34
Smyth, L., Blunt, D. N., Gatov, E., Nagamuthu, C., Croxford, R., Mozessohn, L., & Cheung, M. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.16635 · Cited by 34 · cited 1×
“Other studies have shown either a null association [64, 65] or improved survival [64, 66] in different NHL subtypes.”
Effect of statin use on outcomes of non‐muscle‐invasive bladder cancer
Crivelli, J. J., Xylinas, E. N., Kluth, L. A., da Silva, R. D., Chrystal, J., Novara, G., Karakiewicz, P. I., David, S. G., Scherr, D. S., Lotan, Y., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12150 · Cited by 33 · cited 1×
“Our results are consistent with a large study of 13,811 bladder cancer patients that found a null association [59], as well as several other smaller studies [60–62].”
E, J.-Y., Lu, S.-E., Lin, Y., Graber, J. M., Rotter, D., Zhang, L., Petersen, G. M., Demissie, K., Lu-Yao, G., & Tan, X.-L. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0227 · Cited by 32
Tsai, H. K., Katz, M. S., Coen, J. J., Zietman, A. L., Kaufman, D. S., & Shipley, W. U. (2006) · Urology · doi:10.1016/j.urology.2006.08.1078 · Cited by 30
Ennishi, D., Asai, H., Maeda, Y., Shinagawa, K., Ikeda, K., Yokoyama, M., Terui, Y., Takeuchi, K., Yoshino, T., Matsuo, K., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp490 · Cited by 30 · cited 1×
“Other studies have shown either a null association [64, 65] or improved survival [64, 66] in different NHL subtypes.”
Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort
Joentausta, R. M., Rannikko, A. S., & Murtola, T. J. (2019) · The Prostate · doi:10.1002/pros.23768 · Cited by 26
Richard, P. O., Ahmad, A. E., Bashir, S., Hamilton, R. J., Nam, R. K., Leao, R. R. N., Claudio Jeldres, A., & Kulkarni, G. S. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.12.009 · Cited by 21
Chan, J. M., Kenfield, S. A., Paciorek, A., Platz, E. A., Giovannucci, E. L., & Stampfer, M. J. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0671 · Cited by 16 · cited 1×
“Our findings are similar to several previous studies that reported a null association [47–50], in contrast with other studies that found a significant association [51–54].”
An, Y., Sun, J., Xu, M., Liu, C., Xu, J., Zhong, X., Hu, J., Xia, Q., Hu, H., & Wang, S. (2022) · Journal of Oncology · doi:10.1155/2022/9275466 · Cited by 13 · cited 1×
“The most recent meta-analysis of eighteen cohort studies found a lower risk of prostate cancer-specific mortality (pooled HR, 0.76; 95% CI, 0.69–0.84), but with significantly high heterogeneity between the studies [55].”
InfluentialLópez, D. S., Huang, D., Tsilidis, K. K., Canfield, S. E., Khera, M., Baillargeon, J., Kuo, Y., Peek, M. K., Platz, E. A., & Markides, K. P. (2021) · Cancer Causes & Control · doi:10.1007/s10552-021-01450-0 · Cited by 11 · cited 1×
“Our findings are similar to several previous studies that reported a null association [47–50], in contrast with other studies that found a significant association [51–54].”
Brånvall, E., Ekberg, S., Eloranta, S., Wästerlid, T., Birmann, B. M., & Smedby, K. E. E. (2021) · British Journal of Haematology · doi:10.1111/bjh.17733 · Cited by 10
Statin use and risks of breast cancer recurrence and mortality
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2024) · Cancer · doi:10.1002/cncr.35362 · Cited by 10
Self-citation
Research works printed but not linked: 3
- Warren JL et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8):3–18
- Enewold L et al (2020) Updated overview of the SEER-medicare data: enhanced content and applications. J Natl Cancer Inst Monogr 2020(55):3–13
- Rubin DB (2009) Multiple Imputation for Nonresponse in Surveys. 2009: Wiley
Cited by
Yang, J., Lin, J., Guo, H., Wu, W., Wang, J., Mao, J., Fan, W., Yang, L., Wang, Y., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638677 · Cited by 7
Self-citationArtner, A., Diler, I., Hankó, B., Sebők, S., & Zelkó, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155436 · Cited by 1
“Third, the temporal relationship between statin initiation and cancer diagnosis remains poorly characterized across studies, potentially affecting the magnitude of observed benefits [56,58].”
Yuan, S., Li, B., Jiang, Y., Shen, L., Fu, Z., & Liu, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1792449 · Cited by 1
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“…on survival was analyzed on statin use duration categories: < 1 year, 1–2 years, 2–3 years, > 3 years, with higher benefits on OS in the 1–2 years category compared to 1 category, and respectively 2–3 years category compared to 1–2 years category, with a p trend value of 0.04 (Guo et al., 2025).”
InfluentialPotassium channels in cancer: from hallmarks to therapeutic targeting
Zhang, Y.-L., Shi, R.-J., & Liang, X. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01228-5
Metadata
- Authors
- Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I.
- Affiliations
- University of Washington (US)
- Corresponding author
- Li, Christopher I.
- Venue
- Cancer Causes & Control
- Published
- 2024-12-25
- Volume
- 36
- Issue
- 4
- Pages
- 443-455
- ISSN
- 0957-5243 (ISSN-L)
- 1573-7225
- OpenAlex
- W4405746232
- Cited by
- 4
- References
- 63
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cancer Causes & Control (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (T32CA09168)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- statins, cancer-specific mortality, cancer survival, lung cancer, pancreatic cancer, prostate cancer, colorectal cancer, bladder cancer, non-Hodgkin lymphoma, statin therapy, dose-response relationship, SEER-Medicare
- MeSH terms
- Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Neoplasms, United States, Survival Rate, SEER Program, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.